Fractyl Health, Inc. (GUTS)

Market Cap	91.59M
Revenue (ttm)	60,000
Net Income (ttm)	-89.11M
Shares Out	48.98M
EPS (ttm)	-1.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	130,961
Open	1.800
Previous Close	1.800
Day's Range	1.770 - 1.900
52-Week Range	0.873 - 7.429
Beta	n/a
Analysts	Buy
Price Target	10.00 (+434.76%)
Earnings Date	May 13, 2025

About GUTS

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering me...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 2, 2024
• Employees: 107
• Stock Exchange: NASDAQ
• Ticker Symbol: GUTS
• Website: https://fractyl.com

Financial Performance

In 2024, Fractyl Health's revenue was $93,000, a decrease of -22.50% compared to the previous year's $120,000. Losses were -$70.43 million, -25.29% less than in 2023.

Analyst Forecast

According to one analyst, the rating for GUTS stock is "Buy" and the 12-month stock price forecast is $10.0.

Price Target

$10.0

(434.76% upside)

Analyst Consensus: Buy